Immunohistochemical evaluation of two antibodies against PD-L1 and prognostic significance of PD-L1 expression in epithelioid peritoneal malignant mesothelioma: A RENAPE study. Issue 10 (October 2017)

• Record Type: Journal Article
• Authors: Valmary-Degano, S.; Colpart, P.; Villeneuve, L.; Monnien, F.; M'Hamdi, L.; Lang Averous, G.; Capovilla, M.; Bibeau, F.; Laverriere, M.-H.; Verriele-Beurrier, V.; Ben Rejeb, H.; Dartigues, P.; Hommell-Fontaine, J.; Gilly, F.-N.; Isaac, S.; Mery, E.
• Is Part Of: European journal of surgical oncology. Volume 43:Issue 10(2017:Oct.)
• Page Start: 1915
• Page End: 1923
• Publication Date: 2017-10
• Subjects: Peritoneal mesothelioma -- Epithelioid subtype -- PD-L1 -- Immunohistochemistry -- Survival; EPMM epithelioid peritoneal malignant mesothelioma -- PD-L1 programmed death-ligand 1 -- PD-1 programmed death 1 -- CRS + HIPEC cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy -- HE hematoxylin and eosin -- TIL tumor-infiltrating lymphocytes -- PTL peritumoral lymphocytes -- FFPE formalin-fixed paraffin-embedded -- TMA tissue microarray; Oncology -- Periodicals; Cancer -- Surgery -- Periodicals; Medical Oncology -- Periodicals; Neoplasms -- surgery -- Periodicals; Cancer -- Chirurgie -- Périodiques; Cancérologie -- Périodiques; Oncologie; Chirurgie (geneeskunde); Electronic journals; Electronic journals -- Sciences; Electronic journals -- Medicine; Electronic journals; 616.994059005
• DOI: 10.1016/j.ejso.2017.05.009
• Languages: English
• ISSNs: 0748-7983

Abstract

Abstract: Background: Epithelioid peritoneal malignant mesothelioma (EPMM) is the most common subtype of this aggressive tumor. We compared two antibodies against PD-L1, a recent theranostic biomarker, and evaluated the prognostic value of PD-L1 expression by mesothelial and immune cells in EPMM. Methods: Immunohistochemistry was performed on 45 EPMM. Clinical and pathological data were extracted from the RENAPE database. Using E1L3N and SP142 clones, inter-observer agreement, PD-L1 expression by mesothelial and immune cells and inter-antibody agreement were evaluated. The prognostic relevance of PD-L1 expression was evaluated in 39 EPMM by univariate and multivariate analysis of overall survival (OS) and progression-free survival (PFS). Results: Inter-observer agreement on E1L3N immunostaining was moderate for mesothelial and immune cells, and fair for mesothelial and poor for immune cells using SP142. Using E1L3N, 31.1% of mesothelial and 15.6% of immune cells expressed PD-L1, and 22.2% of mesothelial and 26.7% of immune cells using SP142. Inter-antibody agreement was moderate. In most positive cases, 1–5% of tumor cells were positive. Using E1L3N, PD-L1 expression by lymphocytes was associated with better OS and PFS by both univariate and multivariate analysis. Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy predicted better prognosis than other treatments. Solid subtype was an independent prognostic factor for worse OS. Conclusion: E1L3N appeared easier to use than SP142 to evaluate PD-L1 expression. A minority of EPMM expressed PD-L1, and only a few cells were positive. PD-L1 expression by immune cells evaluated with E1L3N was an independent prognostic factor in EPMM.